➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Colorcon
Johnson and Johnson
Mallinckrodt
McKesson

Last Updated: September 17, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,114,874


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,114,874 protect, and when does it expire?

Patent 8,114,874 protects ICLUSIG and is included in one NDA.

This patent has seventy-one patent family members in twenty countries.

Summary for Patent: 8,114,874
Title:Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors
Abstract: This invention relates to compounds of the general formula: ##STR00001## in which the variable groups are as defined herein, and to their preparation and use. In particular, the compounds include embodiments in which Ring T is an imidazo[1,2-b]pyridazine ring system, Rings A and B are each aryl and L.sup.1 is --C(O)NR.sup.1-- or --NR.sup.1C(O)--. Uses for the compounds and for compositions containing them include treatment of cancer and other diseases mediated by protein kinases.
Inventor(s): Zou; Dong (Concord, MA), Huang; Wei-Sheng (Acton, MA), Thomas; R. Mathew (Waltham, MA), Romero; Jan Antionette C. (Cambridge, MA), Qi; Jiwei (West Roxbury, MA), Wang; Yihan (Newton, MA), Zhu; Xiaotian (Newton, MA), Shakespeare; William C. (Southborough, MA), Sundaramoorthi; Rajeswari (Chennai, IN), Metcalf, III; Chester A. (Needham, MA), Dalgarno; David C. (Brookline, MA), Sawyer; Tomi K. (Southborough, MA)
Assignee: ARIAD Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:11/644,849
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,114,874
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 8,114,874

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Takeda Pharms Usa ICLUSIG ponatinib hydrochloride TABLET;ORAL 203469-004 Dec 18, 2020 RX Yes No ⤷  Try it Free ⤷  Try it Free Y Y ⤷  Try it Free
Takeda Pharms Usa ICLUSIG ponatinib hydrochloride TABLET;ORAL 203469-001 Dec 14, 2012 RX Yes No ⤷  Try it Free ⤷  Try it Free Y Y ⤷  Try it Free
Takeda Pharms Usa ICLUSIG ponatinib hydrochloride TABLET;ORAL 203469-003 Apr 23, 2015 RX Yes No ⤷  Try it Free ⤷  Try it Free Y Y ⤷  Try it Free
Takeda Pharms Usa ICLUSIG ponatinib hydrochloride TABLET;ORAL 203469-002 Dec 14, 2012 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
Johnson and Johnson
Colorcon
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.